The fail­ure of a Pfiz­er an­ti­body-drug con­ju­gate in its im­por­tant late-stage lung can­cer test is ex­act­ly what the New York drug­mak­er didn’t need.

The as­set...

De­spite be­ing an ear­ly play­er in the gene edit­ing field and de­vel­op­ing nu­mer­ous clin­i­cal pro­grams, Sang­amo Ther­a­peu­tics will be sell­ing off its partswith­out ma­te­ri­al­iz­ing...

Plus news about Defini­um Ther­a­peu­tics, uniQure, Moon­Lake Im­munother­a­peu­tics, Ver­sant Ven­tures, Corx­el Phar­ma­ceu­ti­cals and US WorldMeds.

🇨🇳 BOLD gives up: Bound­less Bio BOLD, which faced clin­i­cal...

De­spite the suc­cess of Ex­elix­is’ oral ty­ro­sine ki­nase in­hibitor in a broad­er pop­u­la­tion, the can­di­date failed to sig­nif­i­cant­ly im­prove sur­vival in col­orec­tal can­cer pa­tients with­out...